Improving outcomes for brain metastases in EGFR mutated NSCLC

Jennifer W. Carlisle, Suresh S. Ramalingam

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA

Correspondence to: Suresh S. Ramalingam, MD. Roberto C. Goizueta Chair in Cancer Research, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road NE, C-4014E, Atlanta, GA 30322, USA.

Email: ssramal@emory.edu.

Provenance: This is an invited article commissioned by the Section Editor Dr. Hengrui Liang, MD (Department of Thoracic Surgery, Guangzhou Medical University, Guangzhou, China).


Submitted Apr 25, 2019. Accepted for publication May 17, 2019.
doi: 10.21037/tlcr.2019.05.08

View this article at: http://dx.doi.org/10.21037/tlcr.2019.05.08

Tyrosine kinase inhibitors (TKIs) of activating epidermal growth factor receptor (EGFR) mutations have revolutionized the care of patients with advanced non-small cell lung cancer (NSCLC) who harbor a targetable EGFR mutation. Compared to platinum doublet chemotherapy, median overall survival (OS) has improved from a historical 8–12 months with chemotherapy alone (1) to 26 months with first generation EGFR TKIs gefitinib and erlotinib (2). Patients treated with the first-generation EGFR TKIs have a 5-year OS rate of nearly 15% in the real-world setting (3). In a recent analysis of the third generation EGFR TKI osimertinib in the 2nd or 3rd line setting at the time of acquired resistance with T790M in phase II trials, median OS was 26.8 months (4). While OS data in patients treated with the third generation EGFR TKI osimertinib in the frontline setting are currently maturing (5), long-term disease control is observed in a sizeable subset of patients. As patients are living longer with this disease, determining the optimal management of associated central nervous system (CNS) metastatic disease has become a pressing issue.

Wu et al. recently published a detailed report of the CNS efficacy of osimertinib in T790M positive NSCLC patients (6), as a pre-planned subgroup analysis of the AURA3 clinical trial (7). A total of 116 patients had CNS disease; among the 46 patients with measurable disease, the CNS objective response rate was 70% in the osimertinib group compared to 30% in the platinum pemetrexed group (6). Seven patients with suspected leptomeningeal disease were included in the osimertinib group, four of whom had either complete or partial radiographic response. Interestingly, 14 patients who received brain radiation within 6 months prior to initiation of osimertinib had a better CNS response rate (64%) than those with more remote or no brain radiation (34%) (6). This analysis demonstrates the efficacy of osimertinib in the treatment of patients with brain metastatic disease, including leptomeningeal disease.

A significant number of patients with EGFR mutated NSCLC develop brain metastases (BM) during the course of their disease. BM are identified at diagnosis in approximately 20–30% patients with EGFR mutated NSCLC (8,9). In patients without BM at diagnosis, the actuarial rate of progressive disease in the brain was 6% at one year and 13% at two years based on a 100 patient cohort treated with gefitinib or erlotinib (8). In a similar cohort of 86 patients with advanced EGFR mutated NSCLC, the incidence of BM was 47% at 3 years, 49% at 4 years, and 53% at 5 years (10). A retrospective analysis comparing sequencing of therapy with the EGFR TKI erlotinib (98% of patients) and either stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) suggested a favorable survival outcome with SRS followed by erlotinib (11). In patients treated with SRS first followed
by erlotinib, the median OS was 46 months, whereas those treated with frontline erlotinib, median OS was only 25 months (11). These analyses were conducted in the era of first generation EGFR TKIs, which have a lower CNS penetration (12) and systemic efficacy than osimertinib (5).

There is limited preclinical and pharmacokinetic data detailing osimertinib penetration into the CNS. Ballard et al. demonstrated in rats, that radio-labeled osimertinib could be detected in the brain after a single dose and persist for 21 days with 4 mg/kg of osimertinib, while gefitinib only showed scant CNS uptake that was undetectable at 24 h with 5 mg/kg dosing (12). A positron emission tomography study also demonstrated markedly more CNS uptake in the brain of cynomolgus monkeys with osimertinib compared to gefitinib (12). While all of the currently available EGFR TKIs are substrates for efflux transporters (12), chemical properties that allow influx can overcome efflux (13). These principles help explain the lower mean CSF concentrations of gefitinib compared to erlotinib (14) and the penetration of osimertinib (13).

Additional information regarding the CNS efficacy of frontline osimertinib was recently published as a pre-planned analysis of the FLAURA clinical trial (15). While baseline CNS imaging was not required, 61 patients treated with osimertinib and 67 patients treated with either gefitinib or erlotinib had known CNS disease at study entry (15). Patients treated with osimertinib had improved CNS progression free survival compared to patients treated with first generation EGFR TKIs (PFS not reached vs. 13.9 months respectively, HR 0.48; 95% CI, 0.26–0.86; P=0.014). The objective response rate in the patients with at least one measurable lesion in 22 patients treated with osimertinib and 19 patients treated with first generation EGFR TKIs was 91% with osimertinib, compared to 68% in the control group (odds ratio 4.6; 95% CI, 0.9–34.9; P=0.066) (15). Encouraging results were also noted in the limited number of patients with radiographic evidence of leptomeningeal disease; four out of five patients treated with osimertinib demonstrated complete radiographic response, and the fifth had stable disease (15).

The impact of prior brain radiotherapy on the efficacy of osimertinib is not well established; of the 50 patients with baseline CNS disease treated as part of the AURA extension and AURA2 trial who were evaluable for response, 19 received radiation within the previous 6 months while 31 received no radiation or radiation over 6 months prior to osimertinib (16). In this analysis, patients with prior recent brain radiation had lower a CNS objective response rate of 32% compared to 68% with remote or no prior radiation (16). This is opposite of the trend seen in the AURA3 CNS analysis (6). In the FLAURA clinical trial, a total of 15 patients treated with osimertinib and 16 patients treated with first generation EGFR TKIs received brain radiation in the 6 months prior to study treatment, but only 6 and 9 respectively had a target lesion evaluable for response, limiting conclusions that can be drawn (15). While more data are awaited, current guidelines recommend consideration of osimertinib in patients with stable, asymptomatic CNS metastatic disease in lieu of upfront local therapy with SRS or WBRT (17,18). This approach has the advantage of avoiding potential side effects of SRS and more importantly WBRT.

The presence of leptomeningeal disease is associated with a poor overall outcome and rapid decline in quality of life. In a recently reported expanded retrospective analysis of 22 asymptomatic patients with EGFR mutant NSCLC treated with osimertinib 80 mg daily among the AURA clinical trial program, the leptomeningeal ORR was 55% (95% CI, 32–76%) and median OS was 18.8 months (95% CI, 6.3–NC months) (19). A higher dose of osimertinib, 160 mg daily, has also shown efficacy associated with levels of cerebral spinal fluid penetration in a study of 32 patients, and follow-up survival analysis is pending (20). Along with the reports of clinical benefit in the AURA3 and FLAURA clinical trials with leptomeningeal disease, there is now hope for this patient subset that has among the worst overall prognosis. The results of ongoing studies with specific focus on CNS disease will shed more light on the efficacy of osimertinib in patients with leptomeningeal disease as well as discrete brain metastatic disease (Table 1).

Care must be taken to avoid lumping patients with surgically resectable solitary metastatic disease or symptomatic disease into a frontline systemic TKI therapy plan, as such patients were generally not included in the clinical trials of osimertinib. In symptomatic patients with BMs, the number, size and location of the metastasis guides the decision for SRS, WBRT, or surgical resection followed by SRS or WBRT. While the 2012 American Society for Radiation Oncology (ASTRO) guidelines recommend WBRT following resection (22), recent practice patterns have transitioned to post-operative SRS to the resection bed (23). For now, available data from the clinical development of osimertinib demonstrate CNS efficacy in patients with or without preceding brain radiation and oral TKI therapy is a well-tolerated option for patients with asymptomatic BMs and leptomeningeal disease.
The ability to achieve control of BM has played a major part in improving survival outcomes for patients with lung cancer; in other oncogene-addicted tumors such as with the anaplastic lymphoma kinase (ALK)-rearranged NSCLC, potent TKIs have resulted in improved control of BM (24,25). This has been the result of development of potent TKIs that have the ability to achieve sufficient CNS drug levels. The advantages of using TKIs with potent CNS activity include improved long-term outcomes, avoidance of local therapy to the brain and overall preservation of quality of life for patients. As our knowledge of acquired resistance mechanisms to the new generation of TKIs improve, it is hoped that novel combination approaches can be developed to improve patient outcomes. The optimal dose of osimertinib for the treatment of LM disease merits further investigation since clinical benefit has been observed with both the 80 mg/d and the 160 mg/d dosing strategies. It will also be important to develop algorithms to guide when radiotherapy should be included for the treatment of CNS disease and situations where targeted therapy alone would be sufficient. In summary, the advent of potent TKIs such as osimertinib, with better CNS penetration, has resulted

Table 1 Ongoing clinical trials of osimertinib for brain metastases and/or leptomeningeal disease (21)

<table>
<thead>
<tr>
<th>ClinicalTrials.Gov Identifier</th>
<th>Title</th>
<th>Phase</th>
<th>Number of patients</th>
<th>Expected completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03497767</td>
<td>A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases</td>
<td>II</td>
<td>80</td>
<td>March 2022</td>
</tr>
<tr>
<td>NCT03535363</td>
<td>Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)</td>
<td>I</td>
<td>40</td>
<td>December 2020</td>
</tr>
<tr>
<td>NCT03769103</td>
<td>Open Label, Multicenter, Phase II Study of Patients With Treatment Naive Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone</td>
<td>II</td>
<td>76</td>
<td>December 2022</td>
</tr>
<tr>
<td>NCT02736513</td>
<td>Pilot, Phase 2 Study Assessing Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases</td>
<td>II</td>
<td>40</td>
<td>May 2020</td>
</tr>
<tr>
<td>NCT03463525</td>
<td>An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C] Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases</td>
<td>Not listed</td>
<td>8</td>
<td>September 2019</td>
</tr>
<tr>
<td>NCT02971501</td>
<td>A Phase II Trial of AZD9291 (Osimertinib) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases</td>
<td>II</td>
<td>98</td>
<td>July 2020</td>
</tr>
<tr>
<td>NCT03257124</td>
<td>An Open Label, Multicenter, Phase II Study of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients Harboring T790M Mutation Who Failed EGFR TKIs and With Brain and/or Leptomeningeal Metastasis</td>
<td>II</td>
<td>80</td>
<td>December 2019</td>
</tr>
<tr>
<td>NCT02972333</td>
<td>Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI</td>
<td>Not listed</td>
<td>150</td>
<td>December 2019</td>
</tr>
</tbody>
</table>
in improved outcomes for patients with oncogene-addicted NSCLC.

**Acknowledgments**

None.

**Footnote**

Conflicts of Interest: SS Ramalingam has served on scientific advisory board and received honoraria from Astra Zeneca, Amgen, Bristol Myers Squibb, Merck, Genentech/Roche, Lilly, Nektar, Loxo, Takeda and Tesaro. SS Ramalingam also receives research support (directed to the institution) from Astra Zeneca, Advaxis, Amgen, Bristol Myers Squibb, Merck, Tesaro and Takeda. JW Carlisle has no conflicts of interest to declare.

**References**


Cite this article as: Carlisle JW, Ramalingam SS. Improving outcomes for brain metastases in EGFR mutated NSCLC. Transl Lung Cancer Res 2019. doi: 10.21037/tlcr.2019.05.08